• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Phathom Pharmaceuticals, Inc. - Common Stock (NQ: PHAT )

    7.430 -0.070 (-0.93%)
    Streaming Delayed Price Updated: 12:55 PM EST, Dec 26, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Phathom Pharmaceuticals, Inc. - Common Stock

    < Previous 1 2 3 4 5 6 7 Next >
    Walmart Posts Upbeat Earnings, Joins Armstrong World Industries, Owens & Minor And Other Big Stocks Moving Higher On Tuesday
    U.S. stocks were mostly lower, with the Nasdaq Composite falling more than 200 points on Tuesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Phathom Pharmaceuticals Announces VOQUEZNA® (vonoprazan) Tablets for Erosive GERD and Associated Heartburn Added to Express Scripts National Formularies for Commercial Patients
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Recap: Phathom Pharmaceuticals Q3 Earnings
    Via Benzinga
    Phathom Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    "Top Pick for 2024": Analyst Bullish On Phathom Pharmaceuticals On Voquezna Launch In Erosive GERD, Projecting $55.6M In Sales
    Needham analyst Joseph Stringer reiterated a Buy rating on Phathom Pharmaceuticals, Inc. (NASDAQ: PHAT),  
    Via Benzinga
    Phathom Pharmaceuticals Announces Expansion of Existing Loan and Security Agreement with Hercules Capital
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces FDA Acceptance for Filing of VOQUEZNA® (vonoprazan) Tablets New Drug Application for the Treatment of Heartburn Associated with Non-Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Commercial Availability of VOQUEZNA® (vonoprazan) Tablets, a Powerful First-In-Class PCAB for the Treatment of Erosive GERD and Relief of Associated Heartburn
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Third Quarter 2023 Results and Recent Business Updates
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Via Benzinga
    Phathom Pharmaceuticals Announces FDA Approval of VOQUEZNA® (vonoprazan) Tablets for the Treatment of Erosive GERD and Relief of Heartburn Associated with Erosive GERD in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    What's Going On With Phathom Pharmaceuticals Stock?
    Phathom Pharmaceuticals Inc (NASDAQ: PHAT) shares are trading higher Monday after the company announced FDA approval of its reformulated vo 
    Via Benzinga
    Exposures Product Safety
    Phathom Pharmaceuticals Announces FDA Approval of Reformulated Vonoprazan Tablets for VOQUEZNA® TRIPLE PAK® (vonoprazan, amoxicillin, clarithromycin) and VOQUEZNA® DUAL PAK® (vonoprazan, amoxicillin) for the Treatment of H. pylori Infection in Adults
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Cramer Likes This Industrial Stock: A 'Well-Run' Company Doing 'A Lot Of Good Things'
    On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended not buying ChargePoint Holdings, Inc. 
    Via Benzinga
    Phathom Pharmaceuticals Announces Vonoprazan NDA Submission for Non-Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Reports Second Quarter 2023 Results
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
    Via Benzinga
    3 Cheap Biotech Stocks That Smart Investors Will Snap Up Now
    One of the safest sectors on the market is biotech. Here are three cheap biotech stocks to buy that are good options for investors. 
    Via InvestorPlace
    Bragar Eagel & Squire, P.C. Is Investigating Integra, Chinook, Phathom, and Akumin and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    Bragar Eagel & Squire, P.C. Is Investigating Phathom, Reata, and Comerica and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
    From Phathom Pharmaceuticals
    Via GlobeNewswire
    ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Phathom Pharmaceuticals, Inc. Investors to Inquire About Securities Class Action Investigation - PHAT
    Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
    Via NewMediaWire
    Exposures Product Safety
    PHATHOM ALERT: Bragar Eagel & Squire, P.C. is Investigating Phathom Pharmaceuticals, Inc. on Behalf of Phathom Stockholders and Encourages Investors to Contact the Firm
    From Bragar Eagel & Squire
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.